Drug Trial Radar · NCT06509334
Trial of JYB1904 in Chronic Spontaneous Urticaria.
Last checked: Nov 19, 2026Latest source record: Nov 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
135
Planned (sponsor's estimate)
Start
Aug 4, 2024
Primary completion
Jul 15, 2026
Study completion Jul 15, 2026
Sponsor
- Lead sponsor
- JemincareIndustry
- Sponsor type
- Industry
- First posted
- Jul 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase II Trial is Meant to Evaluate the Efficacy, Safety and Tolerability of JYB1904 Injection in Patients With Chronic Spontaneous Urticaria.
Conditions
- Chronic Spontaneous Urticaria
Interventions
JYB1904Drug
Participants will receive JYB1904 at week0 and receive placebo at week4,8,12
JYB1904Drug
Participants will receive JYB1904 at week0,8 and receive placebo at week4,12
OmalizumabDrug
Participants will receive Omalizumab every 4 weeks for 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Urticaria activity score used for 7 consecutive days(UAS7)Time frame: Baseline through 16 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University People's Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.